If you're going to have a "messy" quarter, you probably couldn't do it much better than Johnson & Johnson (NYSE: JNJ )
did in the first quarter. Devices and Consumer continue to log
disappointing results, but the higher-margin Pharma business is more
than making up the difference. Priced for total annual returns in the
mid-to-high single digits, Johnson & Johnson isn't the cheapest
health care play these days, but it remains a good all-weather pick with
one of the best-growing large drug franchises.
Continue here:
Johnson & Johnson's Earnings Report Impresses
No comments:
Post a Comment